Dr. Meric-Bernstam is the Chair of the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center), Medical Director of the Institute of Personalized Cancer Therapy. She has extensive experience in novel therapeutics, with a focus on genomically-informed therapeutics, HER2-targeted therapy and antibody-drug conjugates, as well as high throughput -omic technologies and correlative studies. She leads one of the premiere Phase I programs in the world, as well as several large-scale initiatives in precision oncology such as ComboMATCH. She also leads a basic and translational research program centered around cell signaling, biomarker discovery, and molecular therapeutics, with specific focus on antibody-drug conjugates, precision oncology, and patient-derived models.
